Ventyx Biosciences Inc

NASDAQ:VTYX   4:00:00 PM EDT
2.14
+0.09 (+4.39%)
5:43:45 PM EDT: $2.14 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Ventyx Biosciences Inc Stock, NASDAQ:VTYX

12790 El Camino Real, Suite 200, San Diego, California 92130
United States of America
Phone: +1.760.593.4832
Number of Employees: 80

Description

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded on November 21, 2018 and is headquartered in San Diego, CA.